EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

EI

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

Search

Pharma Mar SA

Open

79.05 2.2

Overview

Share price change

24h

Current

Min

77

Max

79.35

Key metrics

By Trading Economics

Income

27M

23M

Sales

18M

56M

P/E

Sector Avg

70.044

34.393

EPS

-0.22

Dividend yield

1.01

Profit margin

41.442

Employees

500

EBITDA

-16M

-1.1M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+21.99% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.01%

2.54%

Next Earnings

28 Oct 2025

Market Stats

By TradingEconomics

Market Cap

-54M

1.4B

Previous open

76.85

Previous close

79.05

Technical Score

By Trading Central

Confidence

Bearish Evidence

Pharma Mar SA Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2025, 17:49 UTC

Major Market Movers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 Aug 2025, 17:18 UTC

Major Market Movers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 Aug 2025, 16:25 UTC

Earnings

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 Aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 Aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 Aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 Aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 Aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 Aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 Aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement 2Q Rev $25.8M >EXOD

11 Aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 Aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 Aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 Aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 Aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 Aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 Aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 Aug 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 Aug 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 Aug 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Comparison

Price change

Pharma Mar SA Forecast

Price Target

By TipRanks

21.99% upside

12 Months Forecast

Average 96.496 EUR  21.99%

High 110 EUR

Low 83 EUR

Based on 2 Wall Street analysts offering 12 month price targets forPharma Mar SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

72.75 / 74.3Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.